An ActRIIA fusion protein got FDA approved for PAH treatment

On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment. PAH, characterized by elevated blood pressure in the arteries connecting the heart and lungs, poses a grave risk of heart failure.

Memora Health, Intermountain Partner on Personalized, AI-Powered Care

What You Should Know: – Memora Health, a provider of intelligent care enablement platforms, and Intermountain Health, an integrated healthcare delivery system, today announced a

March 6, 2024

Low levels of ‘memory strengthening protein’ may serve as early predictor of mild cognitive impairment

Results of a long-term, federally funded study of cognitively healthy adults — most with a family history of Alzheimer’s disease — have added to evidence

July 31, 2023

Affineon Health Raises $5M for AI-Powered Physician Inbox Management

What You Should Know: – Affineon Health, a leader in AI-powered solutions to streamline the inbox for healthcare physicians and providers, today announced successfully closing a $5

February 5, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.